The company stands to receive an equity investment of €10M from the European Innovation Council (EIC), subject to future milestones
This grant further enhances the clinical development of the ContraBand congestive heart failure solution. Restore Medical, an Incentive, Peregrine Ventures Incubator portfolio company, was selected as a high-impact innovator among just 74 companies, out of over 1,000 that applied for the European grant. The ContraBand device is a novel catheter-delivered implant intended for the treatment of CHF, it aims to improve the quality of life for millions of patients around the world.
